Skip to main content
Journal cover image

Determining molecular phenotypes of metastatic breast cancer that respond to the small molecule inhibitor of ErbB1 and ErbB2, lapatinib (GW572016)

Publication ,  Conference
Blackwell, KL; Kaplan, EH; Franco, SX; Marcom, PK; Maleski, JE; Spector, NL; Stocum, MT; Sorensen, MJ; Berger, MS
Published in: BREAST CANCER RESEARCH AND TREATMENT
January 1, 2004

Duke Scholars

Published In

BREAST CANCER RESEARCH AND TREATMENT

ISSN

0167-6806

Publication Date

January 1, 2004

Volume

88

Start / End Page

S30 / S30

Location

San Antonio, TX

Publisher

SPRINGER

Conference Name

27th Annual Charles A Colman San Antonio Breast Cancer Symposium

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Blackwell, K. L., Kaplan, E. H., Franco, S. X., Marcom, P. K., Maleski, J. E., Spector, N. L., … Berger, M. S. (2004). Determining molecular phenotypes of metastatic breast cancer that respond to the small molecule inhibitor of ErbB1 and ErbB2, lapatinib (GW572016). In BREAST CANCER RESEARCH AND TREATMENT (Vol. 88, pp. S30–S30). San Antonio, TX: SPRINGER.
Blackwell, K. L., E. H. Kaplan, S. X. Franco, P. K. Marcom, J. E. Maleski, N. L. Spector, M. T. Stocum, M. J. Sorensen, and M. S. Berger. “Determining molecular phenotypes of metastatic breast cancer that respond to the small molecule inhibitor of ErbB1 and ErbB2, lapatinib (GW572016).” In BREAST CANCER RESEARCH AND TREATMENT, 88:S30–S30. SPRINGER, 2004.
Blackwell KL, Kaplan EH, Franco SX, Marcom PK, Maleski JE, Spector NL, et al. Determining molecular phenotypes of metastatic breast cancer that respond to the small molecule inhibitor of ErbB1 and ErbB2, lapatinib (GW572016). In: BREAST CANCER RESEARCH AND TREATMENT. SPRINGER; 2004. p. S30–S30.
Blackwell, K. L., et al. “Determining molecular phenotypes of metastatic breast cancer that respond to the small molecule inhibitor of ErbB1 and ErbB2, lapatinib (GW572016).” BREAST CANCER RESEARCH AND TREATMENT, vol. 88, SPRINGER, 2004, pp. S30–S30.
Blackwell KL, Kaplan EH, Franco SX, Marcom PK, Maleski JE, Spector NL, Stocum MT, Sorensen MJ, Berger MS. Determining molecular phenotypes of metastatic breast cancer that respond to the small molecule inhibitor of ErbB1 and ErbB2, lapatinib (GW572016). BREAST CANCER RESEARCH AND TREATMENT. SPRINGER; 2004. p. S30–S30.
Journal cover image

Published In

BREAST CANCER RESEARCH AND TREATMENT

ISSN

0167-6806

Publication Date

January 1, 2004

Volume

88

Start / End Page

S30 / S30

Location

San Antonio, TX

Publisher

SPRINGER

Conference Name

27th Annual Charles A Colman San Antonio Breast Cancer Symposium

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences